Supernus Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Pharmaceuticals (SUPN) PT Lowered to $50 at Cowen
August 7, 2019 10:32 AM EDTCowen analyst Ken Cacciatore lowered the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $50.00 (from $55.00) while maintaining an Outperform rating.
The analyst commented, "Q2 results indicate what has been long building, which is that Trokendi & Oxtellar are showing the natural aging process, and... More
